Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-6

Action as in trial updates? That would be disappointing.

I won't be stoked if they do a placement to sophs before announcing cohort 3 interim data. Unless they are sitting on it because it's not very good news?

At current MC, to raise only 2 quarters of funding would be a 20% dilution (plus probably more options handed out). The diution compounds over the years.

I'm really surprised the MC has got so low. I suppose many investors are aware of how expensive cellular therapies, in particular, are to develop. Which may put some big investors off.